Mindy Magee

788 total citations
41 papers, 567 citations indexed

About

Mindy Magee is a scholar working on Infectious Diseases, Hepatology and Virology. According to data from OpenAlex, Mindy Magee has authored 41 papers receiving a total of 567 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Infectious Diseases, 9 papers in Hepatology and 8 papers in Virology. Recurrent topics in Mindy Magee's work include HIV/AIDS drug development and treatment (12 papers), HIV Research and Treatment (8 papers) and Hepatitis C virus research (8 papers). Mindy Magee is often cited by papers focused on HIV/AIDS drug development and treatment (12 papers), HIV Research and Treatment (8 papers) and Hepatitis C virus research (8 papers). Mindy Magee collaborates with scholars based in United States, United Kingdom and Germany. Mindy Magee's co-authors include Christian D. Lates, Robert A. Blum, William J. Jusko, Richard V. Clark, Arun Mandagere, Peter Ackerman, Duncan Richards, Cyril Llamoso, Megan McLaughlin and Ye Li and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Mindy Magee

40 papers receiving 557 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mindy Magee United States	14	124	119	85	77	68	41	567
Jean Michel Petit France	15	317 2.6×	194 1.6×	103 1.2×	67 0.9×	101 1.5×	25	1.1k
Guoli Sun China	12	346 2.8×	88 0.7×	56 0.7×	83 1.1×	27 0.4×	52	1.0k
Shilpa M. Patel India	12	246 2.0×	29 0.2×	109 1.3×	54 0.7×	47 0.7×	41	718
Jonathan Q. Tran United States	19	287 2.3×	35 0.3×	170 2.0×	23 0.3×	33 0.5×	43	1.0k
Heike Meiselbach Germany	14	300 2.4×	66 0.6×	53 0.6×	50 0.6×	48 0.7×	30	666
Linyong Xu China	12	187 1.5×	34 0.3×	90 1.1×	78 1.0×	47 0.7×	35	740
Milton G. Mutchnick United States	20	180 1.5×	78 0.7×	85 1.0×	81 1.1×	35 0.5×	78	1.4k
Sarah Allegra Italy	16	131 1.1×	36 0.3×	248 2.9×	60 0.8×	16 0.2×	59	801
Julio Dávila Spain	12	185 1.5×	44 0.4×	75 0.9×	21 0.3×	25 0.4×	33	759
Chan‐Loi Yong United States	13	162 1.3×	35 0.3×	260 3.1×	24 0.3×	22 0.3×	22	944

Countries citing papers authored by Mindy Magee

Since Specialization

Citations

This map shows the geographic impact of Mindy Magee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mindy Magee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mindy Magee more than expected).

Fields of papers citing papers by Mindy Magee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mindy Magee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mindy Magee. The network helps show where Mindy Magee may publish in the future.

Co-authorship network of co-authors of Mindy Magee

This figure shows the co-authorship network connecting the top 25 collaborators of Mindy Magee. A scholar is included among the top collaborators of Mindy Magee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mindy Magee. Mindy Magee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Han, Kelong, et al.. (2025). Lack of Pharmacokinetic Drug–Drug Interactions Between Bepirovirsen and Nucleos(t)ide Analogs. Clinical Pharmacology in Drug Development. 14(4). 281–291. 2 indexed citations

Nguyen, Dung N., et al.. (2024). No dose adjustment of metformin or substrates of organic cation transporters (OCT)1 and OCT2 and multidrug and toxin extrusion protein (MATE)1/2K with fostemsavir coadministration based on modeling approaches. Pharmacology Research & Perspectives. 12(4). e1238–e1238. 3 indexed citations

Ismail, Mohamed A., et al.. (2024). Population Pharmacokinetics of Bepirovirsen in Healthy Participants and Participants with Chronic Hepatitis B Virus Infection: Results from Phase 1, 2a, and 2b Studies. Infectious Diseases and Therapy. 13(7). 1515–1530. 2 indexed citations

Galluppi, Gerald R., Malidi Ahamadi, Nageshwar Budha, et al.. (2024). Considerations for Industry—Preparing for the FDA Model‐Informed Drug Development (MIDD) Paired Meeting Program. Clinical Pharmacology & Therapeutics. 116(2). 282–288. 6 indexed citations

Marbury, Thomas, et al.. (2024). A Phase 1, Single‐Dose Study to Evaluate the Pharmacokinetics and Safety of Bepirovirsen in Adults with Hepatic Impairment and Healthy Participants (B‐Assured). Clinical Pharmacology in Drug Development. 13(10). 1088–1097. 1 indexed citations

Goteti, Kosalaram, Mindy Magee, Sven Mensing, et al.. (2023). Opportunities and Challenges of Disease Progression Modeling in Drug Development – An IQ Perspective. Clinical Pharmacology & Therapeutics. 114(2). 266–274. 5 indexed citations

Thakkar, Nilay, Mindy Magee, Navin Goyal, et al.. (2023). Model‐Based Dose Selection of Fostemsavir for Pediatric Populations With Multidrug‐Resistant HIV‐1 and Relative Bioavailability Assessment in Healthy Adults. Clinical Pharmacology in Drug Development. 12(10). 991–1000.

Thakkar, Nilay, et al.. (2022). Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants. Antimicrobial Agents and Chemotherapy. 66(4). e0225121–e0225121. 8 indexed citations

Wire, Mary Beth, et al.. (2022). Evaluation of the pharmacokinetic drug-drug interaction between the antiretroviral agents fostemsavir and maraviroc: a single-sequence crossover study in healthy participants. SHILAP Revista de lepidopterología. 23(1). 1–8. 3 indexed citations

10.

Magee, Mindy, et al.. (2019). Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid‐dependent, human immunodeficiency virus seronegative participants. British Journal of Clinical Pharmacology. 85(8). 1771–1780. 11 indexed citations

11.

Rosenfeld, Philip J., Brian B. Berger, Elias Reichel, et al.. (2018). A Randomized Phase 2 Study of an Anti–Amyloid β Monoclonal Antibody in Geographic Atrophy Secondary to Age-Related Macular Degeneration. Ophthalmology Retina. 2(10). 1028–1040. 46 indexed citations

12.

Hu, Chaoying, Debra Tompson, Mindy Magee, et al.. (2015). Single and Multiple Dose Pharmacokinetics, Pharmacodynamics and Safety of the Novel Lipoprotein-Associated Phospholipase A2 Enzyme Inhibitor Darapladib in Healthy Chinese Subjects: An Open Label Phase-1 Clinical Trial. PLoS ONE. 10(10). e0139862–e0139862. 5 indexed citations

13.

Xu, Yanmei, James Roger, Colin H. Macphee, et al.. (2014). Platelet Aggregation Unchanged by Lipoprotein-Associated Phospholipase A2 Inhibition: Results from an In Vitro Study and Two Randomized Phase I Trials. PLoS ONE. 9(1). e83094–e83094. 17 indexed citations

14.

Dave, Mehul, Graeme Young, Harma Ellens, et al.. (2013). Disposition and Metabolism of Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, in Humans. Drug Metabolism and Disposition. 42(3). 415–430. 13 indexed citations

15.

Richards, Duncan, Rebecca Spence, Arun Mandagere, Linda S. Henderson, & Mindy Magee. (2010). Effects of Multiple Doses of Ambrisentan on the Pharmacokinetics of a Single Dose of Digoxin in Healthy Volunteers. The Journal of Clinical Pharmacology. 51(1). 102–106. 8 indexed citations

16.

Harrison, Brooke C., Mindy Magee, Arun Mandagere, et al.. (2010). Effects of Rifampicin (Rifampin) on the Pharmacokinetics and Safety of Ambrisentan in Healthy Subjects. Clinical Drug Investigation. 30(12). 875–885. 16 indexed citations

17.

Spence, Rebecca, Arun Mandagere, Duncan Richards, et al.. (2010). Potential for Pharmacokinetic Interactions Between Ambrisentan and Cyclosporine. Clinical Pharmacology & Therapeutics. 88(4). 513–520. 25 indexed citations

18.

Richards, Duncan, Gennyne Walker, Arun Mandagere, Mindy Magee, & Linda S. Henderson. (2009). Effect of Ketoconazole on the Pharmacokinetic Profile of Ambrisentan. The Journal of Clinical Pharmacology. 49(6). 719–724. 26 indexed citations

19.

Magee, Mindy, Robert A. Blum, Christian D. Lates, & William J. Jusko. (2002). Pharmacokinetic/pharmacodynamic model for prednisolone inhibition of whole blood lymphocyte proliferation. British Journal of Clinical Pharmacology. 53(5). 474–484. 38 indexed citations

20.

Magee, Mindy, Robert A. Blum, Christian D. Lates, & William J. Jusko. (2001). Prednisolone Pharmacokinetics and Pharmacodynamics in Relation to Sex and Race. The Journal of Clinical Pharmacology. 41(11). 1180–1194. 90 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact